Swiss - Delayed Quote CHF

Galderma Group N (GALD.SW)

106.98

-1.52

(-1.40%)

At close: 5:30:07 PM GMT+1

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

ZUG, Switzerland, December 13, 2024--Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcut

Business Wire 30 days ago

GALDY

GDERF
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

ZUG, Switzerland, December 13, 2024--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged

Business Wire last month

GALDY

GDERF
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

ZUG, Switzerland, November 28, 2024--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology.1 The trial met both primary and all key secondary endpoints, showing that nemolizumab-treated patients had significantly higher improvements in itch and skin lesions when compared to those receiving pl

Business Wire last month

GALDY

GDERF
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

ZUG, Switzerland, November 04, 2024--This month marks the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation.1-5,10-16 Sculptra works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance, and has been a cornerstone of Galderma’s broad portfolio of proven aesthetic treatments.17,18 During its 25 years on the market, healthcare professionals have treated m

Business Wire 2 months ago

GALDY

GDERF
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

SINGAPORE, October 25, 2024--Galderma (SWX:GALD), the pure-play dermatology category leader, today announced a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region, which houses some of the company’s fastest growing markets. This is the largest regional event to date and will deliver a premium and engaging experience for more than 650 delegates. Taking place October 26-27 in Incheon, South Korea, the extensive, two-day agenda will take a deep dive into t

Business Wire 2 months ago

GALDY

GDERF
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

ZUG, Switzerland, October 24, 2024--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2024, reporting record net sales and significant progress across its product categories and key future growth drivers.

Business Wire 2 months ago

GALDY

GDERF
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

ZUG, Switzerland, October 21, 2024--Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess™) for frown lines and crow’s feet after repeated injections.1 The READY-4 study met its primary and secondary endpoints, with less than one in five participants experiencing treatment-related treatment-emergent adverse events (TEAEs), and all events deemed mild or moderate.1 Efficacy and patient satisfaction were als

Business Wire 2 months ago

GALDY

GDERF
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

ZUG, Switzerland, September 17, 2024--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024, reinforcing its commitment to advancing dermatology for every skin story. In addition to presenting 30 abstracts with data on prurigo nodularis, atopic dermatitis, sensiti

Business Wire 3 months ago

GALDY

GDERF
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

ZUG, Switzerland, August 13, 2024--Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.1 Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. FDA – a status reserved for medicines with the potential to significantly improve the treatment of serious conditions.

Business Wire 4 months ago

GALDY

GDERF
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

ZUG, Switzerland, August 05, 2024--Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development (R&D) collaboration in the form of a scientific partnership focused on complementary research projects which could develop advanced, future-proof technologies with direct applications in the field of dermatology.

Business Wire 5 months ago

GALDY

GDERF
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

ZUG, Switzerland, July 30, 2024--Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA – previously referred to as QM1114). RelfydessTM is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow’s feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when

Business Wire 5 months ago

GALDY

GDERF
Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

ZUG, Switzerland, July 25, 2024--Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024.

Business Wire 5 months ago

GALDY

GDERF
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance

ZUG, Switzerland, July 25, 2024--Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet.1The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or without TCI, in adolescent and adult patients with moderate-to-severe atopic dermatitis.1 Results

Business Wire 5 months ago

GALDY

GDERF
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin

DALLAS, July 09, 2024--Galderma announced today the exclusive launch in the U.S. of its latest innovations in its Cetaphil range of products: a Vitamin C Serum and a Ceramide Serum.

Business Wire 6 months ago

GDERF
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

ZUG, Switzerland, June 19, 2024--Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap.

Business Wire 6 months ago

GDERF
Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets

ZUG, Switzerland, May 23, 2024--Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT™) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs

Business Wire 7 months ago

GDERF
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries

ZUG, Switzerland, May 07, 2024--Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory authorities are members of the Access Consortium. An approval decision is expected from the consortium next year. Nemolizumab is a therapy specifically inhibiting IL-31 signaling to

Business Wire 8 months ago

GALDY

GDERF
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

ZUG, Switzerland, April 24, 2024--Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024.

Business Wire 8 months ago

GALD.SW
-1.40%

Performance Overview

Return	GALD.SW	MSCI WORLD
YTD	+6.30%	-1.56%
1-Year	+101.85%	+15.55%
3-Year	+101.85%	+13.90%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Galderma Group N (GALD.SW)

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance

Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets

Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

Performance Overview